These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
219 related articles for article (PubMed ID: 38270089)
1. RNA Origami Functions as a Self-Adjuvanted Nanovaccine Platform for Cancer Immunotherapy. Yip T; Qi X; Yan H; Chang Y ACS Nano; 2024 Feb; 18(5):4056-4067. PubMed ID: 38270089 [TBL] [Abstract][Full Text] [Related]
2. A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists. Baljon JJ; Kwiatkowski AJ; Pagendarm HM; Stone PT; Kumar A; Bharti V; Schulman JA; Becker KW; Roth EW; Christov PP; Joyce S; Wilson JT ACS Nano; 2024 Mar; 18(9):6845-6862. PubMed ID: 38386282 [TBL] [Abstract][Full Text] [Related]
3. Antigen epitope-TLR7/8a conjugate as self-assembled carrier-free nanovaccine for personalized immunotherapy. Song H; Su Q; Shi W; Huang P; Zhang C; Zhang C; Liu Q; Wang W Acta Biomater; 2022 Mar; 141():398-407. PubMed ID: 35007785 [TBL] [Abstract][Full Text] [Related]
4. Dual-Targeted Self-Adjuvant Heterocyclic Lipidoid@Polyester Hybrid Nanovaccines for Boosting Cancer Immunotherapy. Liu Z; Liu B; Feng Y; Zhao L; Wang Q; He H; Yin T; Zhang Y; Yang L; Gou J; Tang X ACS Nano; 2024 Jun; 18(24):15557-15575. PubMed ID: 38837909 [TBL] [Abstract][Full Text] [Related]
5. Self-Adjuvanted Molecular Activator (SeaMac) Nanovaccines Promote Cancer Immunotherapy. Luo Z; He T; Liu P; Yi Z; Zhu S; Liang X; Kang E; Gong C; Liu X Adv Healthc Mater; 2021 Apr; 10(7):e2002080. PubMed ID: 33336537 [TBL] [Abstract][Full Text] [Related]
6. Enhanced Antitumor Immune Responses via a Self-Assembled Carrier-Free Nanovaccine. Liu D; Deng B; Liu Z; Ma B; Leng X; Kong D; Ji T; Liu L Nano Lett; 2021 May; 21(9):3965-3973. PubMed ID: 33886338 [TBL] [Abstract][Full Text] [Related]
7. Vaccination of TLR7/8 Agonist-Conjugated Antigen Nanoparticles for Cancer Immunotherapy. Wang N; Zhang G; Zhang P; Zhao K; Tian Y; Cui J Adv Healthc Mater; 2023 Sep; 12(22):e2300249. PubMed ID: 37016572 [TBL] [Abstract][Full Text] [Related]
8. Self-adjuvant Astragalus polysaccharide-based nanovaccines for enhanced tumor immunotherapy: a novel delivery system candidate for tumor vaccines. Li N; Zhang Y; Han M; Liu T; Wu J; Xiong Y; Fan Y; Ye F; Jin B; Zhang Y; Sun G; Sun X; Dong Z Sci China Life Sci; 2024 Apr; 67(4):680-697. PubMed ID: 38206438 [TBL] [Abstract][Full Text] [Related]
9. Self-assembly nanovaccine containing TLR7/8 agonist and STAT3 inhibitor enhances tumor immunotherapy by augmenting tumor-specific immune response. Zhang L; Huang J; Chen X; Pan C; He Y; Su R; Guo D; Yin S; Wang S; Zhou L; Chen J; Zheng S; Qiao Y J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34452929 [TBL] [Abstract][Full Text] [Related]
10. Self-Adjuvanting Polyguanidine Nanovaccines for Cancer Immunotherapy. Zhang X; Wang K; Zhao Z; Shan X; Wang Y; Feng Z; Li B; Luo C; Chen X; Sun J ACS Nano; 2024 Mar; 18(9):7136-7147. PubMed ID: 38407021 [TBL] [Abstract][Full Text] [Related]
11. Minimalist Nanovaccine with Optimized Amphiphilic Copolymers for Cancer Immunotherapy. Niu L; Miao Y; Cao Z; Wei T; Zhu J; Li M; Bai B; Chen L; Liu N; Pan F; Zhu J; Wang C; Yang Y; Chen Q ACS Nano; 2024 Jan; 18(4):3349-3361. PubMed ID: 38230639 [TBL] [Abstract][Full Text] [Related]
12. Toward Personalized Peptide-Based Cancer Nanovaccines: A Facile and Versatile Synthetic Approach. Kakwere H; Ingham ES; Allen R; Mahakian LM; Tam SM; Zhang H; Silvestrini MT; Lewis JS; Ferrara KW Bioconjug Chem; 2017 Nov; 28(11):2756-2771. PubMed ID: 28956907 [TBL] [Abstract][Full Text] [Related]
13. A Universal Cyclodextrin-Based Nanovaccine Platform Delivers Epitope Peptides for Enhanced Antitumor Immunity. Mao J; Jin Z; Rui X; Li L; Hou C; Leng X; Bi X; Chen Z; Chen Y; Wang J Adv Healthc Mater; 2023 Oct; 12(27):e2301099. PubMed ID: 37602523 [TBL] [Abstract][Full Text] [Related]
14. Self-adjuvanting cancer nanovaccines. Liao Z; Huang J; Lo PC; Lovell JF; Jin H; Yang K J Nanobiotechnology; 2022 Jul; 20(1):345. PubMed ID: 35883176 [TBL] [Abstract][Full Text] [Related]
15. Co-assembled nanocomplexes of peptide neoantigen Adpgk and Toll-like receptor 9 agonist CpG ODN for efficient colorectal cancer immunotherapy. Liang Z; Cui X; Yang L; Hu Q; Li D; Zhang X; Han L; Shi S; Shen Y; Zhao W; Ju Q; Deng X; Wu Y; Sheng W Int J Pharm; 2021 Oct; 608():121091. PubMed ID: 34555477 [TBL] [Abstract][Full Text] [Related]
16. Carrier-free subunit nanovaccine amplifies immune responses against tumors and viral infections. Chen H; Li Y; Li L; Yang Z; Wen Z; Liu L; Liu H; Chen Y Acta Biomater; 2023 Mar; 158():525-534. PubMed ID: 36572250 [TBL] [Abstract][Full Text] [Related]
17. Nanovaccines: An effective therapeutic approach for cancer therapy. Gurunathan S; Thangaraj P; Wang L; Cao Q; Kim JH Biomed Pharmacother; 2024 Jan; 170():115992. PubMed ID: 38070247 [TBL] [Abstract][Full Text] [Related]
18. Responsive Multivesicular Polymeric Nanovaccines that Codeliver STING Agonists and Neoantigens for Combination Tumor Immunotherapy. Su T; Cheng F; Qi J; Zhang Y; Zhou S; Mei L; Fu S; Zhang F; Lin S; Zhu G Adv Sci (Weinh); 2022 Aug; 9(23):e2201895. PubMed ID: 35712773 [TBL] [Abstract][Full Text] [Related]
19. Facile preparation of a metal-phenolic network-based lymph node targeting nanovaccine for antitumor immunotherapy. Su Q; Liu Z; Du R; Chen X; Chen L; Fu Z; Luo X; Yang Y; Shi X Acta Biomater; 2023 Mar; 158():510-524. PubMed ID: 36603733 [TBL] [Abstract][Full Text] [Related]
20. Monophosphoryl lipid A-assembled nanovaccines enhance tumor immunotherapy. Li R; Hao Y; Pan W; Wang W; Min Y Acta Biomater; 2023 Nov; 171():482-494. PubMed ID: 37708924 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]